Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Curevac N.V.
(NQ:
CVAC
)
3.240
-0.010 (-0.31%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Curevac N.V.
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stocks That Hit 52-Week Lows On Thursday
August 25, 2022
On Thursday, 63 companies set new 52-week lows.
Via
Benzinga
Fighting Omicron: This Covid Vaccine Candidate Is Going After The Dangerous Mutation
August 18, 2022
Via
Benzinga
CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update
August 18, 2022
Via
ACCESSWIRE
Germany Inks COVID-19 Vaccine Deal With CureVac, GSK Until 2029
April 11, 2022
Via
Benzinga
CureVac - GSK Start Dosing In Next-Gen COVID-19 Vaccine Candidate Trial
March 30, 2022
Via
Benzinga
CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate
August 18, 2022
Via
ACCESSWIRE
BioNTech, Pfizer File For Clearance Over COVID-19 Vaccine Patent Dispute With CureVac
July 26, 2022
Via
Benzinga
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot
July 06, 2022
The company isn't seeking an injunction, but wants "fair compensation."
Via
Investor's Business Daily
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot
July 05, 2022
The company isn't seeking an injunction, but wants "fair compensation."
Via
Investor's Business Daily
CureVac Files COVID-19 Vaccine Patent Infringement Lawsuit Against BioNTech
July 05, 2022
Via
Benzinga
CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech
July 05, 2022
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 5, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Lawsuit
Exposures
COVID-19
Financial
Intellectual Property
CureVac Announces Voting Results of General Meeting
June 22, 2022
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 22, 2022 / CureVac N.V. (Nasdaq:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on...
From
CureVac
Via
AccessWire
Exposures
COVID-19
CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform
June 08, 2022
TÜBINGEN, GERMANY and AMSTERDAM, NETHERLANDS / ACCESSWIRE / June 8, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on...
From
CureVac
Via
AccessWire
CureVac Announces Changes of CDO - Myriam Mendila to Succeed Klaus Edvardsen
June 08, 2022
TÜBINGEN, DEUTSCHLAND and BOSTON, MA / ACCESSWIRE / June 8, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger...
From
CureVac
Via
AccessWire
Billionaire Bill Gates Is Betting Against TSLA Stock. Here’s Where He’s Putting His Money Instead.
May 25, 2022
Earlier this year, it was revealed that Bill Gates had a half a billion dollar short position against TSLA stock. So, what is he bullish on?
Via
InvestorPlace
The Daily Biotech Pulse: Third FDA Rejection For Verrica's Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva's Chikungunya Vaccine
May 25, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development
May 25, 2022
TÜBINGEN, GERMANY and GHENT, BELGIUM / ACCESSWIRE / May 25, 2022 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger...
From
CureVac
Via
AccessWire
Curevac Announces Financial Results For The First Quarter Of 2022 And Provides Business Update
May 25, 2022
TÜBINGEN, GERMANY and BOSTON MA / ACCESSWIRE / May 25, 2022 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger...
From
CureVac
Via
AccessWire
Exposures
COVID-19
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
April 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update
April 28, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
CureVac
Via
AccessWire
Exposures
COVID-19
How To Attend CureVac Q4 2021 Earnings Conference Call
April 25, 2022
CureVac (NASDAQ:CVAC) will host a conference call at 09:00 AM ET on April 28, 2022, to discuss Q4 2021 earnings results. How to Attend CureVac (CVAC) Conference Call Follow this link to access the live...
Via
Benzinga
CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022
April 22, 2022
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 22, 2022 / CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger...
From
CureVac
Via
AccessWire
The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data
April 21, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study
April 21, 2022
- Vaccine candidate combining Beta- and Delta-specific mRNAs shows strong protection and immune responses during preclinical challenge study - Demonstrated neutralizing capacity against the Omicron...
From
CureVac
Via
AccessWire
Exposures
COVID-19
CureVac and GSK Enter into Pandemic Preparedness Contract with German Government
April 11, 2022
- German government reserves domestic manufacturing capacity until 2029 to ensure rapid access to mRNA vaccines developed by CureVac and GSK - Five-year contract enables production of up to 80 million...
From
CureVac
Via
AccessWire
CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV
March 30, 2022
- Phase 1 dose-escalation study started at clinical sites in the U.S. - Milestone demonstrates CureVac's and GSK's continued execution on comprehensive clinical program of second-generation vaccine...
From
CureVac
Via
AccessWire
Exposures
COVID-19
CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer(R)
March 01, 2022
- The RNA Printer(R) is CureVac's integrated and automated manufacturing solution for RNA vaccines and therapeutics - CureVac RNA Printer GmbH to provide dedicated infrastructure to accelerate...
From
CureVac
Via
AccessWire
Exposures
COVID-19
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
February 16, 2022
We've got another busy day of trading ahead of us so let's get right to it with the biggest pre-market stock movers for Wednesday!
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
February 15, 2022
We've got another busy day of trading ahead of us and we're starting with the biggest pre-market stock movers for Tuesday!
Via
InvestorPlace
CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK
February 10, 2022
- Multivalent technology approach for seasonal influenza mRNA vaccine candidate addressing four different influenza strains - Influenza candidate developed in collaboration with GSK within broad...
From
CureVac
Via
AccessWire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.